Short Interest in Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Increases By 64.2%

Key Points

• Short interest in Pharming Group N.V. (NASDAQ:PHAR) increased by 64.2% in September, reaching a total of 11,000 shares.
• Silverberg Bernstein Capital Management LLC raised its position in Pharming Group stock by 8.6% during Q2, now holding 52,147 shares valued at approximately $557,000.
• Brokerages have mixed ratings for Pharming Group, with a consensus rating of "Hold" and a target price of $30.00.

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Get Free Report) was the recipient of a significant growth in short interest in the month of September. As of September 15th, there was short interest totaling 11,000 shares, a growth of 64.2% from the August 31st total of 6,700 shares. Based on an average daily volume of 10,000 shares, the short-interest ratio is presently 1.1 days. Based on an average daily volume of 10,000 shares, the short-interest ratio is presently 1.1 days.

Hedge Funds Weigh In On Pharming Group

An institutional investor recently raised its position in Pharming Group stock. Silverberg Bernstein Capital Management LLC increased its holdings in Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Free Report) by 8.6% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 52,147 shares of the company's stock after purchasing an additional 4,150 shares during the quarter. Silverberg Bernstein Capital Management LLC owned 0.08% of Pharming Group worth $557,000 as of its most recent filing with the Securities & Exchange Commission. 0.03% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have commented on PHAR. Weiss Ratings restated a "sell (d+)" rating on shares of Pharming Group in a research note on Saturday, September 27th. Zacks Research downgraded shares of Pharming Group from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, September 30th. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average target price of $30.00.

Pharming Group Price Performance

NASDAQ PHAR traded down $0.76 on Monday, hitting $15.38. The stock had a trading volume of 9,854 shares, compared to its average volume of 7,424. Pharming Group has a 52-week low of $7.31 and a 52-week high of $17.08. The company has a debt-to-equity ratio of 0.38, a quick ratio of 2.07 and a current ratio of 2.79. The company has a market capitalization of $1.05 billion, a price-to-earnings ratio of -118.31 and a beta of 0.04. The firm has a 50-day moving average of $13.43 and a 200-day moving average of $11.02.

Pharming Group (NASDAQ:PHAR - Get Free Report) last posted its quarterly earnings data on Thursday, July 31st. The company reported $0.06 earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.16. The firm had revenue of $93.20 million for the quarter, compared to analysts' expectations of $70.36 million. Pharming Group had a negative net margin of 2.19% and a negative return on equity of 3.31%. Pharming Group has set its FY 2025 guidance at EPS. Equities analysts expect that Pharming Group will post -0.2 EPS for the current year.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.